GeoVax Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

GeoVax Labs şirketinin toplam hissedar öz sermayesi $8.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $11.1M ve $2.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$8.59m
Eşitlik	US$8.50m
Toplam yükümlülükler	US$2.61m
Toplam varlıklar	US$11.11m

Son finansal sağlık güncellemeleri

Recent updates

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

Dec 27

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Nov 27

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Oct 03

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Aug 14

Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?

Feb 18

GeoVax soars on NIAID grant for COVID-19 vaccine candidate

Jan 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GOVX 'nin kısa vadeli varlıkları ( $10.9M ) kısa vadeli yükümlülüklerini ( $2.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: GOVX un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GOVX borçsuzdur.

Borcun Azaltılması: GOVX şu anda borcu yok ancak 5 yıl öncesine ait verimiz olmadığı için karşılaştırma yapamıyoruz.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: GOVX şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: GOVX un, serbest nakit akışı her yıl % 45.8 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

GeoVax Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

GeoVax Labs Regains Compliance with Nasdaq's Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

GeoVax Labs Receives Letter from Nasdaq Due to Failure to Comply with Nasdaq’s Shareholder Approval Requirements Set Forth in Nasdaq Listing Rule 5635(d)

GeoVax Labs Receives a Notice from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

GeoVax Labs Regains Compliance with Nasdaq Minimum Bid Requirement

GeoVax Announces 1 for 15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

GeoVax Labs Receives a Notice from the Nasdaq Stock Market

Recent updates

GeoVax Labs, Inc. Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs Regains Compliance with Nasdaq's Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

GeoVax Labs, Inc. to Report Q3, 2024 Results on Nov 12, 2024

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $4.486846 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $5.000001 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.499997 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.499997 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.5 million.

Geovax Labs, Inc. Announces Phase 2 Plans for Gedeptin®? Cancer Therapy Following Clinical Advisory Committee Review

GeoVax Labs, Inc. to Report Q2, 2024 Results on Aug 06, 2024

GeoVax Labs Receives Letter from Nasdaq Due to Failure to Comply with Nasdaq’s Shareholder Approval Requirements Set Forth in Nasdaq Listing Rule 5635(d)

GeoVax Labs Receives a Notice from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q1, 2024 Results on May 14, 2024

GeoVax Labs, Inc., Annual General Meeting, May 23, 2024

GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System

New minor risk - Shareholder dilution

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q4, 2023 Results on Feb 29, 2024

GeoVax Labs Regains Compliance with Nasdaq Minimum Bid Requirement

Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster

GeoVax Announces 1 for 15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Geovax Appoints Marc Pipas as Executive Medical Director, Oncology

New major risk - Market cap size

GeoVax Labs Receives a Notice from the Nasdaq Stock Market

Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02

New major risk - Revenue and earnings growth

GeoVax Labs, Inc. to Report Q3, 2023 Results on Nov 08, 2023

GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

New major risk - Financial position

GeoVax Labs, Inc. Announces First Patients Vaccinated in Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc. to Report Q2, 2023 Results on Aug 09, 2023

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc., Annual General Meeting, Aug 01, 2023

GeoVax Labs, Inc. Announces Next-Generation COVID-19 Vaccine Data to Be Presented At Two Upcoming Scientific Meetings

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

Geovax Labs, Inc. Appoints Valerie Montgomery Rice as Special Advisor to the Chairman/CEO and Board of Directors

GeoVax Labs Receives Non-Compliance Notice From Nasdaq

GeoVax Labs, Inc. Appoints Jayne Morgan to Board of Directors

Price target decreased to US$5.50

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021)

High number of new directors

GeoVax Labs, Inc. to Report Q3, 2022 Results on Nov 09, 2022

We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

Geovax Announces Appointment of Nicole Lemerond to Its Board of Directors

GeoVax: Possible Vaccine Advancements In 2 Big Indications

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine

GeoVax Labs, Inc. to Report Q2, 2022 Results on Aug 03, 2022

GeoVax Labs, Inc., Annual General Meeting, Aug 03, 2022

Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky

First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.29 loss in 1Q 2021)

Insufficient new directors

GeoVax Labs, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Geovax Labs, Inc. Announces Management Appointments

GeoVax Labs, Inc. to Report Fiscal Year 2021 Results on Mar 09, 2022

GeoVax Labs, Inc. announced that it has received $9.999998 million in funding

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial for Covid-19 Vaccine Booster

GeoVax Labs, Inc. Presents Hemorrhagic Fever Vaccine Data at World Vaccine & Immunotherapy Congress

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.73 loss in 3Q 2020)

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Geovax Presents Covid-19 Vaccine Data At the European Society of Medicine (Esmed) General Assembly